GRAL
GRAILBNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
+
Peers tracked
11
U.S. public peers
Grade Position
Above peers
vs peer average
GRAL vs peer average
71/100
GRAL vs. peer average (B vs. C)
Grade spread
A 2 · C 4 · D 1 · F 3
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
ARQT is the first available peer comparator.
Arcutis is a loose same-cap biotech comparator from the packet, but not a direct multi-cancer early detection peer; GRAL should trade more on Galleri-specific regulatory and commercialization milestones than broad biotech beta.
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
GRAL
GRAIL
ARQT
Arcutis Biotherapeutics
Grade
B
C
Momentum
86
18
Value
41
41
Sentiment
55
90
Setup Bias
Net Neutral
-
Market Cap
-
-
Posture
Constructive
Mixed
Grade position vs ARQT
GRAL / ARQT
Grade Position
Above peers
GRAL vs. peer average (B vs. C)
71/100
Momentum
86
GRALValue
41
GRALSentiment
55
ARQTRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs GRAL
ARQT is the first peer returned for this comparison set.